Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration Into Clinical Dose Optimization and Toxicity Management

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-2645
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials

Nucleic Acid Therapeutics
BiochemistryMolecular MedicineDrug DiscoveryGeneticsMolecular Biology
2019English

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach

Journal of Clinical Pharmacology
Pharmacology
2017English

Binding of Small Molecule Drugs to Porcine Vitreous Humor

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2018English

Integration of Small-Molecule Discovery in Academic Biomedical Research

Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
2010English

The Benefits From Giving Makers of Conventional 'Small Molecule' Drugs Longer Exclusivity Over Clinical Trial Data

Health Affairs
MedicineHealth Policy
2011English

In Vitro Evaluations of Antimalarial Drugs and Their Relevance to Clinical Outcomes

International Journal for Parasitology
ParasitologyInfectious Diseases
2008English

Integration of Knowledge Processes Into Management Systems

Journal of Energy and Power Engineering
2019English

Strategies of Discovering Small Molecule Drugs Targeting Growth Factor Heregulin

2002English

Self-Management in Patients With Inflammatory Bowel Disease: Strategies, Outcomes, and Integration Into Clinical Care

Clinical and Experimental Gastroenterology
Gastroenterology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy